ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Solasia Pharma KK

Business Summary

Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. It provides patients access to western oncology and hematology therapies by developing products licensed from western pharmaceutical and biotechnology companies. The company was founded by Bard Geesaman, John McDonald, and Koji Shinozaki in December 2006 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2020 JPYUSD
Revenue454M4.25M
Gross Profit-251M-2.35M
Operating income-3,315M-31.04M
Income before tax-4,159M-38.95M
Net income-4,127M-38.65M
EBITDA-2,819M-26.40M
Diluted EPS-35.15-0.32
Dividends Per Share00
Total Assets6,481M62.77M
Total liabilities2,827M27.38M
Total equity3,652M35.37M
Operating cash flow-2,789M-26.12M
Currency in JPYCurrency in USD

Historical Data

 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 501.31M 410.85M 318M 1,310M 454M
Gross Profit 500.43M 410.32M -48M 770M -251M
Operating income -462.47M -1,009.68M -2,419M -1,761M -3,315M
Income before tax -494.63M -1,016.28M -2,445M -1,797M -4,159M
Net income -474.43M -1,007.48M -2,422M -1,867M -4,127M
EBITDA -461.59M -1,009.15M -2,266M -1,286M -2,819M
Diluted EPS -18.46 -12.24 -25.97 -17.74 -35.15
Dividends Per Share -- 0 0 0 0
Total Assets 4,451.44M 7,566.64M 8,672M 8,944M 6,481M
Total liabilities 1,017.97M 1,358.08M 1,584M 2,025M 2,827M
Total equity 3,433.46M 6,208.55M 7,087M 6,917M 3,652M
Operating cash flow -464.98M -911.39M -2,323M -828M -2,789M
 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 4.61M 3.66M 2.87M 12.01M 4.25M
Gross Profit 4.60M 3.65M -0.43M 7.06M -2.35M
Operating income -4.25M -9.00M -21.90M -16.15M -31.04M
Income before tax -4.55M -9.06M -22.13M -16.48M -38.95M
Net income -4.36M -8.98M -21.92M -17.12M -38.65M
EBITDA -4.24M -8.99M -20.51M -11.79M -26.40M
Diluted EPS -0.16 -0.10 -0.23 -0.16 -0.32
Dividends Per Share -- 0 0 0 0
Total Assets 38.16M 67.16M 79.04M 82.30M 62.77M
Total liabilities 8.72M 12.05M 14.43M 18.63M 27.38M
Total equity 29.43M 55.11M 64.59M 63.64M 35.37M
Operating cash flow -4.27M -8.12M -21.03M -7.59M -26.12M

Valuation Measures

Dec 2020
PER--
ROA-53.51%
ROE-78.09%
Operating margin-730.17%
Profit margin-909.03%

Key executives

  • President & Representative Director: Yoshihiro Arai
  • CFO, Director & General Manager-Administration: Toshio Miyashita
  • Manager-Business Development: Koji Shinozaki
  • General Manager-Marketing: Yasuaki Manabe
  • Manager-Accounting: Yasumitsu Shimada

Shareholders

  • ITOCHU Corp. (17.4%)
  • Maruho Co., Ltd. (8.6%)
  • Lee's Pharmaceutical Holdings Ltd. (2.2%)
  • IMAMURA HITOSHI /CHIBA/ (0.8%)
  • Kyoto KK (0.7%)
  • YAMANA KIYOSHI /FUKUYAMA/ (0.6%)
  • ARAI YOSHIHIRO (0.4%)
  • Solasia Pharma Employee Incentive Plan (0.3%)
  • MIYASHITA TOSHIO /SOLASIA/ (0.3%)
  • BlackRock Japan Co., Ltd. (0.2%)

Contact Details

  • Website:http://www.solasia.co.jp
  • Address: Sumitomo Fudosan Shiba-Koen Tower 4F, 2-11-1 Shiba-koen, Tokyo, 105-0011, Japan
  • Phone: +81.3.5843.8045

Related Companies

  • Solasia Pharma Employee Incentive Plan

Competitors

    Last Updated on 15 Jun, 2021

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Try 1 month for $0.99

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends January 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to Nikkei Asia has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more